Brief: Todos Medical Retains CRO For COVID-19 Outpatient And Inpatient Clinical Trials
28/07/2021 14:22
July 28 (Reuters) - Todos Medical Ltd TOMDF.PK :
* TODOS MEDICAL RETAINS CRO FOR COVID-19 OUTPATIENT AND
INPATIENT
PHASE 2/3 CLINICAL TRIALS FOR ORAL ANTIVIRAL 3CL PROTEASE
INHIBITOR TOLLOVIR
* TODOS MEDICAL LTD - EXPECTS ENROLLMENT FOR BOTH TRIALS TO
BEGIN
IN Q3 OF 2021 WITH INITIAL, TRIAL EXPANSION-ENABLING DATA
EXPECTED IN Q4 OF 2021
Source text for Eikon: ID:nGNX4vXV4w
Further company coverage: TOMDF.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Todos Medical
See all newsBrief: Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network
Brief: Todos Medical Clia/Cap Lab Provista Submits Emergency Use Authorization Application For Monkeypox Pcr Test To Us FDA
Brief: Todos Medical Provides Corporate Update
Brief: Todos Medical Enters Into $50 Mln Contract To Supply Tollovid, CBD Products To Retail Distributor Company Nerd Hemp
Brief: Todos Medical Establishes Botanical Supplement Manufacturing Capabilities